Arbutus Biopharma Corporation (NASDAQ:ABUS) insider Michael J. Sofia sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the completion of the transaction, the insider now directly owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Arbutus Biopharma Corporation (NASDAQ:ABUS) remained flat at $3.60 on Friday. The company had a trading volume of 17,707 shares. The stock’s 50-day moving average price is $3.67 and its 200 day moving average price is $3.30. Arbutus Biopharma Corporation has a 12-month low of $2.35 and a 12-month high of $4.04. The stock’s market capitalization is $198.09 million.

WARNING: “Arbutus Biopharma Corporation (ABUS) Insider Sells $111,000.00 in Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/19/arbutus-biopharma-corporation-abus-insider-sells-111000-00-in-stock.html.

A number of research firms recently commented on ABUS. Zacks Investment Research cut Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Finally, Ladenburg Thalmann Financial Services began coverage on Arbutus Biopharma Corporation in a report on Friday, June 2nd. They issued a “buy” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Arbutus Biopharma Corporation has an average rating of “Buy” and a consensus price target of $11.65.

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Arbutus Biopharma Corporation by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP increased its position in Arbutus Biopharma Corporation by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the period. Renaissance Technologies LLC increased its position in Arbutus Biopharma Corporation by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the period. Victory Capital Management Inc. purchased a new position in Arbutus Biopharma Corporation during the second quarter valued at $478,000. Finally, Bank of Montreal Can increased its position in Arbutus Biopharma Corporation by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares during the period. Institutional investors own 66.49% of the company’s stock.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Receive News & Stock Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related stocks with our FREE daily email newsletter.